Phase I/II, Open Label, Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Pacritinib (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 05 Sep 2017 Status changed from suspended to withdrawn prior to enrolment.
- 01 Sep 2016 Status changed from not yet recruiting to suspended as FDA has placed all trials involving Pacritinib on Full Clinical Hold .
- 17 Feb 2016 New trial record